RGD Reference Report - Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.

Authors: Maatta, M  Talvensaari-Mattila, A  Turpeenniemi-Hujanen, T  Santala, M 
Citation: Maatta M, etal., Anticancer Res. 2007 Jul-Aug;27(4C):2753-8.
RGD ID: 2298520
Pubmed: PMID:17695443   (View Abstract at PubMed)

BACKGROUND: Matrix metalloproteinase-2 (MMP-2) (gelatinase A) and MMP-9 (gelatinase B) have the ability to degrade several extracellular matrix components. This study aimed to evaluate whether matrix metalloproteinases (MMP-2, MMP-9, MMP-2-TIMP-2 complex) or their tissue inhibitors (TIMP-1, TIMP-2) could be used as preoperative serum markers in differentiating between low malignant potential (LMP) and malignant ovarian tumours. PATIENTS AND METHODS: The study population consisted of 61 patients with ovarian neoplasms (28 benign, 11 LMP and 22 malignant). MMP-2, MMP-9, MMP-2-TIMP-2 complex, TIMP-1 and TIMP-2 were analysed from serum samples using enzyme-linked immunoassay (ELISA). RESULTS: Serum TIMP-1 values significantly increased from benign (median 250 microg/l, range 137-616 microg/l) to LMP (median 357 microg/l, range 63-587 microg/l) and further to malignant (median 443 microg/l, range 199-983 microg/l) ovarian neoplasms (p<0.001). There was a significant difference in the ratios of TIMP-1 to MMP-2 and TIMP-1 to MMP-2-TIMP-2 complex between the patients with benign vs. malignant and an LMP vs. malignant tumour. CONCLUSION: The value of circulating TIMP-1 and the ratios of TIMP-1 to MMP-2 and TIMP-1 to MMP-2-TIMP-2 complex may be valuable for differentiating between LMP and malignant ovarian tumours.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
ovarian cancer disease_progressionIEP 2298520protein:increased expression:serumRGD 
ovarian cancer disease_progressionISOTIMP1 (Homo sapiens)2298520; 2298520protein:increased expression:serumRGD 

Objects Annotated

Genes (Rattus norvegicus)
Timp1  (TIMP metallopeptidase inhibitor 1)

Genes (Mus musculus)
Timp1  (tissue inhibitor of metalloproteinase 1)

Genes (Homo sapiens)
TIMP1  (TIMP metallopeptidase inhibitor 1)


Additional Information